The era of “suggested” medical device cybersecurity practices is officially over. Recently, the FDA has moved from offering guidance to enforcing a non-negotiable mandate. The cause for this dramatic shift is Section 524B of the Consolidated Appropriations Act, 2023. Now fully enforceable, this amendment grants the agency the authority to issue a Refuse to Accept (RTA) ruling for any premarket submission lacking crucial security documentation. This is far more than an IT checklist item; it’s a profound shift in risk management. A cybersecurity lapse is no longer a mere technical oversight—it’s a fundamental business risk that threatens a product’s market viability and can jeopardize a medtech firm’s very existence.

Section 524B: The Small Medtech Vulnerability

Section 524B specifically targets “cyber devices”—any device with software connecting to a network. This re-focus is where small medtech firms face their greatest challenge. The mandate imposes three key, non-negotiable requirements for premarket approval:

1. a detailed software bill of materials (SBOM)
2. a rigorous, secure product development framework (SPDF) plan
3. a comprehensive post-market vulnerability management plan.

Startups have long struggled with what’s known as “prioritization debt,” often treating security as something to handle much later—typically in a “Phase 3” stage. Section 524B changes that approach by moving security to the forefront, requiring it to be built into the design process from the start. This means companies must plan ahead, document thoroughly, and rely on specialized expertise.

For many smaller firms, this poses a real challenge. They often lack both the internal talent and the budget for high-end security tools, making it difficult to build the required threat models and vulnerability assessments for submission. The cost of falling short is steep: missing this documentation almost guarantees an FDA “Refuse to Accept” (RTA) decision, leading to major delays and financial setbacks.

Cybersecurity Gaps Are the New Product Defects

It may seem strange, but we must now consider an unmitigated software vulnerability a critical product defect. The potential for patient harm is identical, of course, but the source of failure has undoubtedly changed.

We are navigating a perilous convergence known as cyber-physical risk. Traditional risk analysis focused on a physical device malfunction, like a faulty valve. Today, the higher threat is a malicious actor remotely controlling a life-sustaining device—a compromised insulin pump or pacemaker—to cause physical injury. This is the new high-water mark of medtech risk.

Unsurprisingly, this shift fundamentally blurs the lines of insurance, specifically between two policies: product liability and cyber liability. Traditionally, product liability insurance only covered injuries caused by design or manufacturing defects. But when a cyberattack takes advantage of a known, unpatched vulnerability, responsibility now falls on the company’s post-market security plan—a key requirement under Section 524B.

This is the moment where the risk management matrix becomes your most critical tool. When a software vulnerability is deemed an unmitigated product defect on the matrix (e.g., high likelihood, critical impact), it demands immediate attention from both operational and insurance perspectives.

In this new environment, companies must have strong cyber liability insurance. These policies must specifically account for cyber-physical risks and the substantial costs of post-market remediation, including mandatory software patches and patient notifications. Insurers are well aware of the 524B mandate and are increasingly requiring proof of compliance before issuing coverage or offering favorable rates. Today, a solid security plan isn’t just good practice—it’s the cost of being insurable.

Actionable Risk Management Steps for Lean Operations

For medtech firms operating with lean budgets, compliance with 524B is not about hiring an expensive security division; it’s about smart, cost-effective risk management. You can balance innovation with security by implementing these four budget-conscious strategies:

• First, you must “shift left” with threat modeling. The highest return on your security investment comes from integrating it into the earliest design input phase. Fixing a vulnerability during concept development is exponentially cheaper than a costly post-market remediation. Utilize simplified methodologies like STRIDE to systematically identify and document security risks, thereby fulfilling a core component of the FDA’s Secure Product Development Framework (SPDF) without overspending.
• Second, embrace the Virtual CISO (vCISO) Model. Instead of hiring a full, expensive security team, contract a vCISO or a specialized firm focused on medtech risk and regulatory compliance. This provides you with the high-level, on-demand expertise necessary to develop the process and documentation required for a 524B submission—a fraction of the cost of a full-time executive.
• Third, automate the SBOM. The software bill of materials is a non-negotiable requirement and the essential “ingredient list” for managing risk. It’s tricky to create this manually. Consider investing in automated software composition analysis (SCA) tools, many of which offer affordable startup tiers. This critical tool not only meets FDA requirements but also enables your hospital customers to trust and manage your device’s risk profile.
• Finally, plan for post-market resilience. Your 524B submission must include a clear, documented plan for timely updates and patches. This commitment demonstrates that you are viewing security through the lens of the total product lifecycle, a crucial risk indicator for the FDA. Proactive patching is the final necessary step in showing you are serious about long-term risk reduction.

Moving Forward with Resilience

Compliance with Section 524B is no longer optional; it is now a prerequisite for market access. For small medtech, this means viewing cybersecurity not as a regulatory checklist item, but as a core quality attribute—a fundamental part of the product itself. Firms that proactively adopt a Security-by-Design approach today are doing more than just meeting a mandate. They are building a more resilient, more insurable, and ultimately more successful business capable of earning the FDA’s trust. In this new, high-stakes regulatory environment, proactive, strategic risk management is the true path to both patient safety and market leadership.